Pages that link to "Q45245896"
Jump to navigation
Jump to search
The following pages link to The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein (Q45245896):
Displaying 50 items.
- Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy (Q26780502) (← links)
- CYP2D6 polymorphisms and their influence on risperidone treatment (Q28079227) (← links)
- Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice (Q28482464) (← links)
- New atypical antipsychotics for schizophrenia: iloperidone (Q30482195) (← links)
- Relationship between P-glycoprotein and second-generation antipsychotics. (Q34208133) (← links)
- The AmpliChip CYP450 genotyping test: Integrating a new clinical tool (Q34537662) (← links)
- Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein (Q34543291) (← links)
- Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10 (Q35287206) (← links)
- Comparative Pharmacology of Risperidone and Paliperidone (Q35807345) (← links)
- Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. (Q36511686) (← links)
- Metabolic drug interactions with newer antipsychotics: a comparative review. (Q36703845) (← links)
- Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population (Q36747019) (← links)
- Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia (Q36873906) (← links)
- A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoprotein (Q36914175) (← links)
- ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (Q36954728) (← links)
- Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study (Q36969067) (← links)
- The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia (Q36984231) (← links)
- Transporter-mediated uptake into cellular compartments (Q36985076) (← links)
- The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. (Q37024001) (← links)
- Pharmacogenomics: the promise of personalized medicine for CNS disorders. (Q37272534) (← links)
- Importance of drug transporters in pharmacokinetics and drug safety (Q37658682) (← links)
- Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides. (Q37726997) (← links)
- Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes (Q37964574) (← links)
- Psychotropic drug-drug interactions involving P-glycoprotein (Q38047816) (← links)
- The pharmacology and formulation of paliperidone extended release (Q38067139) (← links)
- An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. (Q38416672) (← links)
- The blood-brain barrier in psychosis (Q38646326) (← links)
- Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. (Q39552320) (← links)
- Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype (Q39795136) (← links)
- Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone (Q42135650) (← links)
- Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. (Q42185986) (← links)
- The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study (Q42517186) (← links)
- Serum Concentrations of Paliperidone after Administration of the Long-Acting Injectable Formulation (Q42697406) (← links)
- Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. (Q42717938) (← links)
- Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety (Q43120631) (← links)
- Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein (Q43148773) (← links)
- P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. (Q43260115) (← links)
- Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats (Q44176429) (← links)
- Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study (Q44600279) (← links)
- CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies (Q44624989) (← links)
- Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. (Q45991893) (← links)
- Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. (Q46039809) (← links)
- Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? (Q46124016) (← links)
- Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia (Q46548791) (← links)
- P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments (Q46666362) (← links)
- Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice (Q46800432) (← links)
- The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions (Q48273932) (← links)
- Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients (Q48391405) (← links)
- Risperidone and paliperidone inhibit p-glycoprotein activity in vitro (Q48435526) (← links)
- The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites (Q48471800) (← links)